Compass pathways stock forecast.

When a company is developing a novel therapy, sometimes good news takes an unusual form. For Compass Pathways, ( CMPS -8.84%) whose COMP360 program aims to address treatment-resistant depression ...Fresh off IPO, Compass sees mushrooming opportunity in psilocybin....CMPS Psychedelic company Compass Pathways PLC (CMPS) got off to a stellar start of trading on Friday, as investors hungry for the next new thing bought up shares. The U.K....LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...COMPASS Pathways has a market cap of $299.3 million, and a 52-week range of $6.74 to $49.52. The stock has a price/book ratio of 1.32, and a price-to-free-cash-flow ratio of -6.9.COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

COMPASS Pathways PLC Sponsored ADR (CMPS Quick Quote CMPS - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective.Recently, CMPS's ...COMPASS Pathways PLC Sponsored ADR (CMPS Quick Quote CMPS - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective.Recently, CMPS's ...Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...

About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

49.33R USD +43.50 +746.20%. The 6 analysts offering 1 year price forecasts for COMPASS Pathways Plc - American Depository Shares have a max estimate of 120.00 …I last covered the company for Seeking Alpha back in September 2021 when Compass' share price traded at $32.6 and its market cap was ~$1.4bn, and despite arguably making some significant progress ...Stock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, continuing what has been a multi-day uptrend for CMPS stock.; CMPS stock is now up ...

COMPASS Pathways is a business that is trying to treat a serious form of depression ... Patents, Financials, and Forecast. COMPASS is pre ... COMPASS Pathways is an extremely risky stock, ...

2 พ.ย. 2566 ... Stock FTCH logo. FTCH · Farfetch Will Not Announce Third Quarter 2023 ... price prior to the financing, and will be exercisable at the election ...

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2021, COMPASS Pathways had cash of US$294m and no debt ...WebCompass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 18 and 19 and 21 If the stock moves up, then it will find resistance near these levels.Nov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. We note that hedge funds don't have a meaningful investment in COMPASS Pathways. Atai Life Sciences N.V. is currently the company's largest shareholder with 19% of shares outstanding. The second ...49.33R USD +43.50 +746.20%. The 6 analysts offering 1 year price forecasts for COMPASS Pathways Plc - American Depository Shares have a max estimate of 120.00 …Find the latest analyst research for COMPASS Pathways Plc American Depository Shares (CMPS) at Nasdaq.com.Web

COMPASS Pathways PLC (CMPS) stock is down -1.77% while the S&P 500 is higher by 1.89% as of 2:59 PM on Thursday, Apr 27. CMPS has fallen -$0.15 from the previous closing price of $8.17 on volume of 236,713 shares. Over the past year the S&P 500 has fallen -1.22% while CMPS has fallen -21.27%. CMPS lost -$0.01 per share the …Cash position at 30 June 2022 of $207.2 million. Conference call today at 8:00am ET (1:00pm UK) COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to ...17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: CMPS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week. Volatility Over Time: CMPS's weekly volatility (9%) has been stable over the past year.With its shares down by 60% in the last 12 months and a recent layoff affecting 30% of its workforce, it's fair to say that Atai Life Sciences ( ATAI 1.87%) is having a rough go of things lately ...Bid Price and Ask Price. The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is ...

17 ต.ค. 2565 ... Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics.COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the following year, the 0 analysts predict that COMPASS Pathways's EBIT will drop by 35.91%, reaching $-47.15M. In 2030, the professionals' prediction is that CMPS's EBIT will decrease ...

COMPASS PATHWAYS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie COMPASS Pathways PLC (spons. ADRs) | A2QCDR | CMPS | US20451W1018COMPASS Pathways (CMPS) Fundamentals Checker. Financial metrics are used to evaluate financial stability which helps analysts determine if COMPASS Pathways is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Some... Within the last quarter, Compass Pathways (NASDAQ:CMPS) has observed the following analyst...10 stocks we like better than COMPASS Pathways When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, ...COMPASS Pathways (CMPS) Stock Forecast & Price Prediction. Estimation of the future price movement of COMPASS Pathways stock, based on various factors such as …Compare with up to 5 Stocks. On Thursday 11/30/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.20 on NAS. Compared to the opening price on Thursday 11/30/2023 on NAS ...

Nonetheless, Atai remains one of the leaders in the psychedelics segment of the biotech industry, and it holds a 22.4% stake in Compass Pathways, which is one of the other leaders. So if Compass ...Web

It may have a tough pill to swallow, but I'm still optimistic about psilocybin in general, and especially Cybin....CMPS At the time of publication, Tim Collins was long CYBN. Look how quickly we got bulled up. Let's check sentiment, the...

The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744.What is the current Price Target and Forecast for COMPASS Pathways (CMPS) COMPASS Pathways (CMPS) (Real Time Quote from BATS) $5.93 USD +0.10 …CMPS Earnings Date and Information. COMPASS Pathways last posted its quarterly earnings data on November 2nd, 2023. The reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.17. COMPASS Pathways has generated ($2.59) earnings per share over the last year ( ($2.59) diluted …WebCOMPASS Pathways (CMPS) Stock Forecast & Price Target $5.93 -0.05 (-0.84%) (As of 11/29/2023 ET) Compare Today's Range $5.84 $6.25 50-Day Range …Track COMPASS Pathways (CMPS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors Nov 9, 2021 · What happened. Compass Pathways ( CMPS 6.61%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ... Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ... COMPASS Pathways is a mental healthcare company that specializes in psilocybin therapy. Read more to see my thoughts on CMPS stock and why it is a Hold. ... CMPS Stock Forecast.Web

Get a real-time COMPASS Pathways plc (CMPS) stock price quote with breaking news, financials, statistics, charts and more.The average Compass stock price prediction forecasts a potential upside of 35.39% from the current COMP share price of $2.43. What is COMP's forecast return on equity (ROE) for 2023-2026? ( NYSE : COMP ) forecast ROE is N/A , which is considered weak . TipRanks69.32%. Get the latest Compass Pathways PLC (CMPS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Instagram:https://instagram. george soros companieshow to start rental property businessis lumico life insurance legitbarostim reviews COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the following year, the 0 analysts predict that COMPASS Pathways's EBIT will drop by 35.91%, reaching $-47.15M. In 2030, the professionals' prediction is that CMPS's EBIT will decrease ... These psychedelic sector stocks are generating a buzz among investors. ... Compass Pathways PLC -26.3%: Incannex Healthcare Ltd. -69.6% ... Commercial Real Estate Outlook for 2024. foreign exchange market brokerszion gas and oil stock price Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The average price target for CMPS is …WebWe are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. News & events. News releases; Events; Presentations; SEC filings & annual reports; Our annual review; Stock information. Stock quote & chart; Historical price lookup; Analyst Coverage; Split history; Corporate ... ecn stock COMPASS Pathways PLC Sponsored ADR (CMPS Quick Quote CMPS - Free Report) reached a significant support level, and could be a good pick for investors from a technical perspective.Recently, CMPS's ...The financials. The average price target from the nine analysts following COMPASS pathways is $68 against a current price of $14.9, implying a 356% upside and a target market cap of $3 billion. I ...Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...Web